C WorldWide Group Holding A S Purchases Shares of 180,000 Boston Scientific Corporation $BSX

C WorldWide Group Holding A S acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 180,000 shares of the medical equipment provider’s stock, valued at approximately $11,295,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of BSX. Outfitters Financial LLC increased its holdings in Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after buying an additional 110 shares during the period. Natural Investments LLC lifted its stake in Boston Scientific by 2.9% during the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after acquiring an additional 112 shares during the period. Old Port Advisors boosted its holdings in shares of Boston Scientific by 4.7% in the 4th quarter. Old Port Advisors now owns 2,558 shares of the medical equipment provider’s stock valued at $244,000 after acquiring an additional 115 shares during the last quarter. Thrive Wealth Management LLC boosted its holdings in shares of Boston Scientific by 1.6% in the 4th quarter. Thrive Wealth Management LLC now owns 7,387 shares of the medical equipment provider’s stock valued at $704,000 after acquiring an additional 117 shares during the last quarter. Finally, Kathmere Capital Management LLC increased its stake in shares of Boston Scientific by 2.3% in the fourth quarter. Kathmere Capital Management LLC now owns 5,228 shares of the medical equipment provider’s stock worth $498,000 after acquiring an additional 118 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 3.6%

BSX stock opened at $44.58 on Friday. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm’s fifty day moving average is $48.38 and its 200 day moving average is $66.02. The firm has a market cap of $66.26 billion, a PE ratio of 18.65, a P/E/G ratio of 0.82 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BSX. Needham & Company LLC reduced their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. BTIG Research reaffirmed a “buy” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Tuesday, June 16th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Jefferies Financial Group decreased their price objective on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Finally, Leerink Partners lowered their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research note on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.84.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.